The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
Open accessAbstract
BACKGROUND: In a previous pooled analysis of 12 double-blind clinical studies that included data on 6,139 patients with type 2 diabetes, treatment with sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, was shown to be generally well tolerated compared with treatment with control agents. As clinical development of sitagliptin continues, additional studies have been completed, and more patients have been exposed to sitagliptin. The purpose of the present analysis is to update the safety and tolerability assessment of sitagliptin by pooling data from 19 double-blind clinical studies. METHODS: The present analysis included data from 10,246 patients with type 2 diabetes who received either sitagliptin 100 mg/day (N = 5,429; sitagliptin group) or a comparator agent (placebo or an active comparator) (N = 4,817; non-exposed group). The 19 studies from which this pooled population was drawn represent the double-blind, randomized studies that included patients treated with the usual clinical dose of sitagliptin (100 mg/day) for between 12 weeks and 2 years and for which results were available as of July 2009. These 19 studies assessed sitagliptin taken as monotherapy, initial combination therapy with metformin or pioglitazone, or as add-on combination therapy with other antihyperglycemic agents (metformin, pioglitazone, a sulfonylurea +/- metformin, insulin +/- metformin, or rosiglitazone + metformin). Patients in the non-exposed group were taking placebo, metformin, pioglitazone, a sulfonylurea +/- metformin, insulin +/- metformin, or rosiglitazone + metformin. The analysis used patient-level data from each study to evaluate between-group differences in the exposure-adjusted incidence rates of adverse events. RESULTS: Summary measures of overall adverse events were similar in the sitagliptin and non-exposed groups, except for an increased incidence of drug-related adverse events in the non-exposed group. Incidence rates of specific adverse events were also generally similar between the two groups, except for increased incidence rates of hypoglycemia, related to the greater use of a sulfonylurea, and diarrhea, related to the greater use of metformin, in the non-exposed group and constipation in the sitagliptin group. Treatment with sitagliptin was not associated with an increased risk of major adverse cardiovascular events. CONCLUSIONS: In this updated pooled safety analysis of data from 10,246 patients with type 2 diabetes, sitagliptin 100 mg/day was generally well tolerated in clinical trials of up to 2 years in duration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury
Mehta, R. L., Kellum, J. A., Shah, S. V., Molitoris, B. A., Ronco, C., Warnock, D. G., Levin, A., & the Acute Kidney Injury Network (2007) · Critical Care · doi:10.1186/cc5713 · Cited by 7,048
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 1×
“However, interest in the effect of specific antihyperglycemic therapies on cardiovascular outcomes, which was first raised as a result of the University Group Diabetes Program [37], has resurfaced subsequent to a meta-analysis that indicated an increased risk for cardiovascular events with rosiglitazone [38].”
ResultStatistical Methods in Cancer Research. Volume II – The Design and Analysis of Cohort Studies
Juul, S. (1989) · Scandinavian Journal of Social Medicine · doi:10.1177/140349488901700214 · Cited by 3,592
Statistical methods in cancer research. Volume II--The design and analysis of cohort studies.
Breslow, N. E., & Day, N. E. (1987) · PubMed · Cited by 1,684
Comparative analysis of two rates
Miettinen, O., & Nurminen, M. (1985) · Statistics in Medicine · doi:10.1002/sim.4780040211 · Cited by 1,110
Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,065
(1970) · PubMed · Cited by 976
Aschner, P., Kipnes, M. S., Lunceford, J. K., Sanchez, M., Mickel, C., Williams-Herman, D. E., & for the Sitagliptin Study 021 Group (2006) · Diabetes Care · doi:10.2337/dc06-0703 · Cited by 880
Self-citationCharbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G., & for the Sitagliptin Study 020 Group (2006) · Diabetes Care · doi:10.2337/dc06-0706 · Cited by 790
Nauck, M. A., Meininger, G., Sheng, D., Terranella, L., Stein, P. P., & Sitagliptin Study 024 Group (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00704.x · Cited by 667
Incretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 649
Raz, I., Hanefeld, M., Xu, L., Caria, C., Williams-Herman, D., Khatami, H., & Sitagliptin Study 023 Group (2006) · Diabetologia · doi:10.1007/s00125-006-0416-z · Cited by 614
Self-citationGiovannucci, E., & Michaud, D. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.050 · Cited by 543
Hermansen, K., Kipnes, M., Luo, E., Fanurik, D., Khatami, H., Stein, P., & Sitagliptin Study 035 Group (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00744.x · Cited by 525
Incidence, aetiology and epidemiology of uterine fibroids
Okolo, S. (2008) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2008.04.002 · Cited by 515
Rosenstock, J., Brazg, R., Andryuk, P. J., Lu, K., & Stein, P. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.10.007 · Cited by 514
Goldstein, B. J., Feinglos, M. N., Lunceford, J. K., Johnson, J., Williams-Herman, D. E., & for the Sitagliptin 036 Study Group (2007) · Diabetes Care · doi:10.2337/dc07-0627 · Cited by 509
Self-citationRobins, J., Breslow, N., & Greenland, S. (1986) · Biometrics · doi:10.2307/2531052 · Cited by 476
Kennedy, L. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79145-5 · Cited by 427
Use of Thiazolidinediones and Fracture Risk
Meier, C., Kraenzlin, M. E., Bodmer, M., Jick, S. S., Jick, H., & Meier, C. R. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.8.820 · Cited by 355
Does diabetes therapy influence the risk of cancer?
Smith, U., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1441-5 · Cited by 316
Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus
Richter, B., Bandeira-Echtler, E., Bergerhoff, K., & Lerch, C. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006739.pub2 · Cited by 308 · cited 1×
“Prior meta-analyses of published studies of DPP-4 inhibitors (including sitagliptin and vildagliptin) have reported an increased risk for infections overall and for specific infections (nasopharyngitis, upper respiratory tract infection, and urinary tract infection) [9,26,34].”
BackgroundEfficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
Vilsbøll, T., Rosenstock, J., Yki‐Järvinen, H., Cefalu, W. T., Chen, Y., Luo, E., Musser, B., Andryuk, P. J., Ling, Y., Kaufman, K. D., et al. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01173.x · Cited by 305 · cited 4×
“Prior meta-analyses of published studies of DPP-4 inhibitors (including sitagliptin and vildagliptin) have reported an increased risk for infections overall and for specific infections (nasopharyngitis, upper respiratory tract infection, and urinary tract infection) [9,26,34].”
BackgroundResultInfluentialSelf-citationScott, R., Wu, M., Sanchez, M., & Stein, P. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01246.x · Cited by 260
Raz, I., Chen, Y., Wu, M., Hussain, S., Kaufman, K. D., Amatruda, J. M., Langdon, R. B., Stein, P. P., & Alba, M. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x260925 · Cited by 260
Self-citationSafety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
Chan, J. C. N., Scott, R., Arjona Ferreira, J. C., Sheng, D., Gonzalez, E., Davies, M. J., Stein, P. P., Kaufman, K. D., Amatruda, J. M., & Williams‐Herman, D. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00914.x · Cited by 238
Self-citationBrown, N. J., Byiers, S., Carr, D., Maldonado, M., & Warner, B. A. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.134197 · Cited by 231
Scott, R., Loeys, T., Davies, M. J., Engel, S. S., & for the Sitagliptin Study 801 Group (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00839.x · Cited by 223
Self-citationSeck, T., Nauck, M., Sheng, D., Sunga, S., Davies, M. J., Stein, P. P., Kaufman, K. D., Amatruda, J. M., & for the Sitagliptin Study 024 Group (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02353.x · Cited by 208
Self-citationVella, A., Bock, G., Giesler, P. D., Burton, D. B., Serra, D. B., Saylan, M. L., Dunning, B. E., Foley, J. E., Rizza, R. A., & Camilleri, M. (2007) · Diabetes · doi:10.2337/db07-0136 · Cited by 201
New Drugs for the Treatment of Diabetes: Part II: Incretin-Based Therapy and Beyond
Inzucchi, S. E., & McGuire, D. K. (2008) · Circulation · doi:10.1161/circulationaha.107.735795 · Cited by 187
Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials
Monami, M., Iacomelli, I., Marchionni, N., & Mannucci, E. (2010) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.03.015 · Cited by 174
Aschner, P. J., Katzeff, H. L., Guo, H., Sunga, S., Williams‐Herman, D., Kaufman, K. D., Goldstein, B. J., & for the Sitagliptin Study 049 Group (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01187.x · Cited by 166
Self-citationKarasik, A., Aschner, P. J., Katzeff, H. L., Davies, M. J., & Stein, P. P. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x261069 · Cited by 163
Self-citationMohan, V., Yang, W., Son, H.-Y., Xu, L., Noble, L., Langdon, R. B., Amatruda, J. M., Stein, P. P., & Kaufman, K. D. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.10.009 · Cited by 161
Self-citationHanefeld, M., Herman, G. A., Wu, M., Mickel, C., Sanchez, M., Stein, P. P., & on behalf of the Sitagliptin Study 014 investigators (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x188152 · Cited by 160
Williams‐Herman, D., JOHNSON, J. R., Teng, R., Golm, G. T., Kaufman, K. D., Goldstein, B. J., & Amatruda, J. M. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01204.x · Cited by 158
Self-citationDipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema
Byrd, J. B., Touzin, K., Sile, S., Gainer, J. V., Yu, C., Nadeau, J., Adam, A., & Brown, N. J. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.096552 · Cited by 147 · cited 1×
“Reduced DPP-4 enzyme activity and DPP-4 enzyme deficiency have been associated with an increase in ACE inhibitor-induced angioedema in rats and humans [46,47], and it was hypothesized that concomitant use of DPP-4 inhibitors and ACE inhibitors could increase the risk of angioedema-related adverse events.”
BackgroundSitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis
Engel, S. S., Williams‐Herman, D., Golm, G. T., Clay, R. J., Machotka, S. V., Kaufman, K. D., & Goldstein, B. J. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02382.x · Cited by 143
Self-citationWilliams‐Herman, D., Johnson, J. R., Teng, R., Luo, E., Davies, M. J., Kaufman, K. D., Goldstein, B. J., & Amatruda, J. M. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990802705679 · Cited by 134
Self-citationThiazolidinediones and Fractures in Men and Women
Dormuth, C. R., Carney, G., Carleton, B., Bassett, K. L., & Wright, J. M. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.214 · Cited by 133
Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis
Williams‐Herman, D., Round, E., Swern, A. S., Musser, B. J., Davies, M. J., Stein, P. P., Kaufman, K. D., & Amatruda, J. M. (2008) · BMC Endocrine Disorders · doi:10.1186/1472-6823-8-14 · Cited by 132
Self-citationMcGuire, D. K., & Inzucchi, S. E. (2008) · Circulation · doi:10.1161/circulationaha.107.704080 · Cited by 130
Byrd, J. B., Shreevatsa, A., Putlur, P., Foretia, D., McAlexander, L., Sinha, T., Does, M. D., & Brown, N. J. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.04.012 · Cited by 52 · cited 1×
“Reduced DPP-4 enzyme activity and DPP-4 enzyme deficiency have been associated with an increase in ACE inhibitor-induced angioedema in rats and humans [46,47], and it was hypothesized that concomitant use of DPP-4 inhibitors and ACE inhibitors could increase the risk of angioedema-related adverse events.”
BackgroundBenign Skin Lesions: Lipomas, Epidermal Inclusion Cysts, Muscle and Nerve Biopsies
Pandya, K. A., & Radke, F. (2009) · Surgical Clinics of North America · doi:10.1016/j.suc.2009.03.002 · Cited by 42
GLP-1: Broadening the incretin concept to involve gut motility
Hellström, P. M. (2009) · Regulatory Peptides · doi:10.1016/j.regpep.2009.04.004 · Cited by 30
Rationale and design of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
Bethel, M. A., Green, J., Califf, R. M., & Holman, R. R. (2009) · Diabetologia · Cited by 30
Efficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-analysis
Amori, R. E., Lau, J., & Pittas, A. G. (2007) · JAMA · doi:10.1001/jama.298.2.194 · Cited by 12
Cited by
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review
Deacon, C. F. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01306.x · Cited by 525
Handelsman, Y., Mechanick, J. I., Blonde, L., Grunberger, G., Bloomgarden, Z. T., Bray, G. A., Dagogo-Jack, S., Davidson, J. A., Einhorn, D., Ganda, O., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.s2.1 · Cited by 513
Nauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429
Metadata
- Authors
- Williams-Herman, D., Engel, S. S., Round, E., Johnson, J., Golm, G. T., Guo, H., Musser, B. J., Davies, M. J., Kaufman, K. D., & Goldstein, B. J.
- Venue
- BMC Endocrine Disorders
- Published
- 2010-04-22
- Volume
- 10
- Issue
- 1
- Pages
- 7-7
- ISSN
- 1472-6823 (ISSN-L)
- OpenAlex
- W2150849997
- Cited by
- 258
- References
- 49
- FWCI
- 30.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.